Top Page
SinoMab Bioscience Ltd.
(3681)
SinoMab Bioscience Ltd. (3681) vs. iShares MSCI Hong Kong ETF (EWH)
SinoMab Bioscience Ltd. Business Overview & Revenue Model
SinoMab Bioscience Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.03M | 1.36M | 4.03M | 26.66M | 12.76M |
| Gross Profit | 543.00K | 422.00K | 4.03M | 26.66M | 12.76M |
| EBITDA | -142.79M | -200.46M | -244.29M | -296.43M | -158.61M |
| Net Income | -185.14M | -243.11M | -284.16M | -288.19M | -122.60M |
Balance Sheet | |||||
| Total Assets | 753.10M | 847.79M | 1.01B | 1.04B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 106.88M | 234.66M | 422.38M | 589.53M | 916.20M |
| Total Debt | 482.27M | 450.81M | 357.18M | 275.46M | 97.84M |
| Total Liabilities | 560.19M | 552.20M | 498.77M | 361.43M | 142.51M |
| Stockholders Equity | 192.91M | 295.58M | 509.57M | 680.23M | 987.01M |
Cash Flow | |||||
| Free Cash Flow | -172.30M | -237.74M | -413.29M | -345.30M | -217.29M |
| Operating Cash Flow | -130.80M | -133.85M | -300.54M | -147.06M | -141.34M |
| Investing Cash Flow | -94.48M | -96.92M | -81.36M | -137.70M | -179.22M |
| Financing Cash Flow | 73.27M | 82.27M | 102.28M | 57.52M | -18.81M |
SinoMab Bioscience Ltd. Technical Analysis
SinoMab Bioscience Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$45.38B | 51.01 | 31.65% | ― | 4.23% | 47.71% | |
57 Neutral | HK$17.81B | ― | -21.42% | ― | 240.05% | -140.09% | |
55 Neutral | HK$3.75B | ― | -75.64% | ― | 42.21% | 29.52% | |
54 Neutral | HK$47.13B | ― | -19.78% | ― | 25.96% | 39.58% | |
47 Neutral | HK$47.06B | ― | -45.12% | ― | 47.62% | 28.72% | |
46 Neutral | C$218.58M | -0.35 | -24.12% | 3.15% | 18.55% | -0.65% | |
41 Neutral | HK$3.73B | ― | -69.97% | ― | ― | 3.30% |
SinoMab Bioscience Ltd. Corporate Events
SinoMab BioScience Limited has completed the subscription of new shares under a general mandate, issuing 157,107,000 shares, which represents approximately 11.54% of the company’s enlarged share capital. The net proceeds from these subscriptions, amounting to approximately HK$318,782,210, will be used for clinical trials, pre-clinical research, and general corporate purposes, with the funds expected to be fully utilized by the end of 2027. This strategic move is anticipated to strengthen SinoMab’s operational capabilities and support its ongoing and future drug development initiatives.
SinoMab BioScience Limited has entered into a three-year strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong to conduct joint research and development in biomedicine. This collaboration aims to leverage mutual expertise in scientific research, drug development, and technical support, with a focus on advancing therapeutics for debilitating diseases. The agreement includes joint usage of facilities, training programs, and a funding commitment from SinoMab to support the projects, enhancing the company’s operational capabilities and industry positioning.
SinoMab BioScience Limited announced the grant of 46,585,862 share options to 20 employees and two service providers under its 2022 Share Option Scheme. This move is part of the company’s strategy to incentivize and retain talent, aligning employee performance with company growth. The share options, exercisable over an eight-year period starting from July 2027, are tied to performance evaluations, ensuring that the grantees’ contributions are rewarded. The absence of a clawback mechanism is justified by existing protective measures within the scheme rules.
SinoMab Bioscience Ltd. announced the conditional agreement to issue 182,072,400 new shares to 23 subscribers at a subscription price of HK$2.03 per share, representing a significant discount to recent trading prices. This move, which does not require shareholder approval, is expected to raise approximately HK$369.46 million in net proceeds, which the company plans to utilize for strategic purposes. The issuance of these shares will expand the company’s share capital by approximately 13.13%, potentially impacting its market positioning and offering new opportunities for growth.
SinoMab BioScience Limited has voluntarily withdrawn its biologics license application for SM03 (Suciraslimab) in the treatment of rheumatoid arthritis in China. This decision follows an internal assessment and recent communications with the Center for Drug Evaluation of the NMPA, highlighting the need for additional evidence of early therapeutic benefits. Despite this setback, the company remains confident in Suciraslimab’s potential and is planning new clinical development for its use in treating systemic lupus erythematosus. SinoMab continues to advance its broader pipeline, which includes multiple innovative drug candidates in various stages of development.
SinoMab BioScience Ltd. announced the results of its Annual General Meeting held on June 30, 2025, where all proposed resolutions, except one that was withdrawn, were approved by shareholders. The resolutions included the re-election of directors, authorization for directors’ remuneration, re-appointment of auditors, and mandates for share buybacks and issuance, indicating strong shareholder support and strategic alignment in the company’s governance and operational plans.
SinoMab BioScience Limited has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which includes executive, non-executive, and independent non-executive directors, as well as the membership of the board’s committees. This update is significant for stakeholders as it reflects the company’s governance and strategic direction, potentially impacting its operations and market positioning.
SinoMab BioScience Limited has adopted new terms of reference for its Nomination Committee, which will be composed of at least three members, primarily independent non-executive directors, with a focus on diversity. This move is in compliance with the listing requirements of the Hong Kong Stock Exchange and aims to enhance the company’s governance structure, potentially impacting its operational efficiency and stakeholder confidence.
SinoMab BioScience Limited announced the resignation of Mr. Shanchun Wang from his position as an executive director and from directorships in certain subsidiaries, effective June 9, 2025. Mr. Wang resigned to focus on personal commitments and confirmed no disagreements with the board, indicating a smooth transition. This change in leadership may impact the company’s strategic direction, but the company has not indicated any immediate operational disruptions.
SinoMab BioScience Limited has announced the composition of its board of directors and their respective roles within the company. This update includes the appointment of Dr. Shui On Leung as both Chairman and CEO, alongside a mix of executive, non-executive, and independent non-executive directors. The announcement also details the membership of the board’s committees, highlighting the company’s structured governance approach, which could enhance its strategic decision-making and operational oversight.
SinoMab BioScience Limited has announced the postponement and change of venue for its 2025 Annual General Meeting (AGM) due to administrative reasons. Originally scheduled for June 13, 2025, the AGM will now take place on June 30, 2025, at a new location in Hong Kong. Additionally, the book closure period for determining shareholders’ entitlement to attend and vote at the AGM has been adjusted. The withdrawal of an ordinary resolution concerning the re-election of an independent director, due to his passing, was also noted. These changes are expected to impact the company’s operational schedule and shareholder engagement.
SinoMab BioScience Limited announced the passing of Mr. Dylan Carlo Tinker, an independent non-executive director and a member of both the audit and nomination committees. This unfortunate event has left the company temporarily non-compliant with the Hong Kong Stock Exchange’s listing rules, as the nomination committee no longer has a majority of independent non-executive directors. The company plans to appoint a suitable replacement within three months to rectify this situation. Additionally, due to Mr. Tinker’s passing, the resolution for his re-election will be withdrawn from the upcoming annual general meeting agenda.
SinoMab BioScience Limited has announced the composition of its board of directors and their respective roles within the company. This announcement provides clarity on the leadership structure, which is crucial for stakeholders and investors as it may influence the company’s strategic direction and governance.
SinoMab BioScience Limited has successfully completed the subscription of new shares under a general mandate, issuing a total of 112,810,817 shares. This issuance represents approximately 9.37% of the company’s enlarged share capital and has raised net proceeds of about HK$123,956,911, which will be used as previously disclosed. This move is expected to impact the company’s shareholding structure and potentially enhance its financial position and market presence.